LakeShore Biopharma Co., Ltd. - רווח נקי למניה אחת בשנים עשר החודשים האחרונים LSB

LakeShore Biopharma Co. relies on a defensive sovereign cycle which, combined with streamlined cold chain logistics, ensures high margins. The GURU.Markets portal shows annual growth in basic net income per share (ttm), where reflects the latest value of the metric. This price action confirms the expansion of the R&D pipeline and the development of Chinese capacities for the global rollout of innovative vaccines.

This indicator measures the rate of change in net earnings per share over a twelve-month period, reflecting the actual efficiency of capital generation relative to historical performance. For LakeShore Biopharma Co. (LSB), which maintains impeccable compliance and status as a leading vaccine supplier, the trailing twelve-month EPS YoY trend visualizes the stability of fundamental shifts, allowing investors to promptly identify market revaluations or business stagnation.